The acquired product line includes several interventional spine pain products including the CDS Discography System, Spinecath and Acutherm Catheters and a full radiofrequency product line. NeuroTherm will also be a distributor of the Trucath Injection System within the interventional spine pain market.

Larry Hicks, president and CEO of NeuroTherm, said: “This acquisition made perfect sense for us, and will go a long way towards sustaining NeuroTherm’s position in the interventional pain space. The Smith & Nephew product line is highly complementary to ours and significantly expands our product offering. This is an exciting opportunity that will enable us to offer a one-stop option for our customers.”

Jos Kerstens, VP of International Sales, said: “We have set plans in place to combine the experience and product knowledge of the two worldwide sales teams to allow us to provide our global customer base with excellent products and a single point of contact. NeuroTherm actively sells interventional pain products into 58 countries around the world. We remain focused on helping physicians expand their practice and offer improved patient care to patients who suffer from chronic pain.”

NeuroTherm is a manufacturer of products used in the field of interventional pain, including radio frequency generators and related consumables used to treat chronic pain. The company has been awarded a US Patent 7,574,257 in recognition of the multi-lesion radiofrequency generator launch.

NeuroTherm markets and sells to interventional pain, interventional radiology, orthopedic and foot & ankle specialists. Foot & Ankle physicians use radiofrequency to treat pain associated with plantar fasciitis & neuroma.

Smith & Nephew is a global medical technology business, specialising in orthopaedics, including reconstruction, trauma and clinical therapies; endoscopy and advanced wound management. Smith & Nephew is a provider in arthroscopy and advanced wound management and is one of the orthopaedics companies.